drugset / Trial / NCT03178123
The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a phase II randomized, control, multi-center study of recombinant humanized anti-PD-1 mAb for injection compared to high-Dose interferon in patients with mucosal melanoma that has been removed by surgery.
Timeline
- Start
- 2017-05-31
- Primary completion
- 2022-04-30
- Completion
- 2025-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Interferon-a2b | Protein / enzyme biologic | 1.5e+10 unknown | Intravenous |
| Subject | Toripalimab | Monoclonal antibody | 3 mg/kg | Intravenous |